Summit Therapeutics Inc. (SMMT) Institutional Ownership

Ownership Summary

Summit Therapeutics Inc. (NASDAQ:SMMT) currently has 15 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in Summit Therapeutics moved to 0.0% in December 2025, a shift down from the 0.1% reported for September 2025.
• The company experienced a 31.88% quarterly change in institutional shares held, alongside a decrease of 92.65% in total owners annually.
• A review of institutional activity for Summit Therapeutics shows 4 of 15 filers increasing their positions, while 5 reduced their stake, and 6 remained unchanged.
• The total number of shares held by institutions in Summit Therapeutics increased to 226.39K as of December 2025, a net change of up by 54.73K shares quarter on quarter, and down 93.87Mn shares year over year.
• As of December 31, 2025, Polianta Ltd held Summit Therapeutics's largest shareholding position with over 74.70K shares, representing 0.00% of total outstanding shares.
• Among the most significant buyers of Summit Therapeutics during December 2025 were Assenagon Asset Management S.A. (59.62K), SG Americas Securities, LLC (10.47K), Rialto Wealth Management, LLC (29), Versant Capital Management, Inc (10).
• Leading sellers of Summit Therapeutics stock in December 2025 included Wealth Management Partners, LLC (15.14K), GAMMA Investing LLC (173), NISA INVESTMENT ADVISORS, LLC (64), JFS WEALTH ADVISORS, LLC (22), True Wealth Design, LLC (1).
• The top 10 institutional holders of Summit Therapeutics for the quarter ending December 2025 included Polianta Ltd (74.70K), Assenagon Asset Management S.A. (59.62K), Wealth Management Partners, LLC (59.43K), SG Americas Securities, LLC (15.59K), Three Seasons Wealth, LLC (12.87K), ADIRONDACK TRUST CO (2.50K), GAMMA Investing LLC (805), Rosenberg Matthew Hamilton (501), NISA INVESTMENT ADVISORS, LLC (237), ORG Partners LLC (40).